Long-term clinical variation of NT-proBNP in stable chronic heart failure patients.

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. / Schou, Morten; Gustafsson, Finn; Kjaer, Andreas; Hildebrandt, Per R.

In: European Heart Journal, Vol. 28, No. 2, 2007, p. 177-82.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Schou, M, Gustafsson, F, Kjaer, A & Hildebrandt, PR 2007, 'Long-term clinical variation of NT-proBNP in stable chronic heart failure patients.', European Heart Journal, vol. 28, no. 2, pp. 177-82. https://doi.org/10.1093/eurheartj/ehl449

APA

Schou, M., Gustafsson, F., Kjaer, A., & Hildebrandt, P. R. (2007). Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. European Heart Journal, 28(2), 177-82. https://doi.org/10.1093/eurheartj/ehl449

Vancouver

Schou M, Gustafsson F, Kjaer A, Hildebrandt PR. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. European Heart Journal. 2007;28(2):177-82. https://doi.org/10.1093/eurheartj/ehl449

Author

Schou, Morten ; Gustafsson, Finn ; Kjaer, Andreas ; Hildebrandt, Per R. / Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. In: European Heart Journal. 2007 ; Vol. 28, No. 2. pp. 177-82.

Bibtex

@article{2c8834e0accd11ddb538000ea68e967b,
title = "Long-term clinical variation of NT-proBNP in stable chronic heart failure patients.",
abstract = "AIMS: Here, the aim is to assess long-term clinical variation (CV) of N-terminal pro-brain natriuretic peptide (NT-proBNP) in stable chronic heart failure (CHF) patients. The proposed use of NT-proBNP for monitoring of CHF patients will require accurate information about long-term CV of the peptide. METHODS AND RESULTS: Medication, biochemical variables, and NYHA class were recorded at 1-year and 2-year follow-up in patients treated in our heart failure clinic. Only patients without changes in medication and the NYHA class who were not hospitalized or died in the period from first follow-up to 12 months after the second follow-up were included. A total of 78 patients fulfilled the criteria, and year-to-year CV was calculated to 30{\%} (median) (range: 0-111{\%}) ({\%} changes range: -87 to 397{\%}). Log transformation of NT-proBNP (skewed to the right) reduced the year-to-year CV to 4.7{\%} (range: 0-22{\%}) ({\%} changes range: -18 to 38{\%}). CONCLUSION: Long-term CV of plasma concentrations of NT-proBNP in stable CHF patients is 30{\%}, but the variation is substantial. Therefore, high long-term CV of NT-proBNP does not necessarily carry prognostic significance within the subsequent 12 months. Plasma concentrations of NT-proBNP followed a lognormal distribution, and the low CV of log(NT-proBNP) indicate that NT-proBNP levels are constant during stable conditions.",
author = "Morten Schou and Finn Gustafsson and Andreas Kjaer and Hildebrandt, {Per R}",
note = "Keywords: Aged; Chronic Disease; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Time Factors",
year = "2007",
doi = "10.1093/eurheartj/ehl449",
language = "English",
volume = "28",
pages = "177--82",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "2",

}

RIS

TY - JOUR

T1 - Long-term clinical variation of NT-proBNP in stable chronic heart failure patients.

AU - Schou, Morten

AU - Gustafsson, Finn

AU - Kjaer, Andreas

AU - Hildebrandt, Per R

N1 - Keywords: Aged; Chronic Disease; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Time Factors

PY - 2007

Y1 - 2007

N2 - AIMS: Here, the aim is to assess long-term clinical variation (CV) of N-terminal pro-brain natriuretic peptide (NT-proBNP) in stable chronic heart failure (CHF) patients. The proposed use of NT-proBNP for monitoring of CHF patients will require accurate information about long-term CV of the peptide. METHODS AND RESULTS: Medication, biochemical variables, and NYHA class were recorded at 1-year and 2-year follow-up in patients treated in our heart failure clinic. Only patients without changes in medication and the NYHA class who were not hospitalized or died in the period from first follow-up to 12 months after the second follow-up were included. A total of 78 patients fulfilled the criteria, and year-to-year CV was calculated to 30% (median) (range: 0-111%) (% changes range: -87 to 397%). Log transformation of NT-proBNP (skewed to the right) reduced the year-to-year CV to 4.7% (range: 0-22%) (% changes range: -18 to 38%). CONCLUSION: Long-term CV of plasma concentrations of NT-proBNP in stable CHF patients is 30%, but the variation is substantial. Therefore, high long-term CV of NT-proBNP does not necessarily carry prognostic significance within the subsequent 12 months. Plasma concentrations of NT-proBNP followed a lognormal distribution, and the low CV of log(NT-proBNP) indicate that NT-proBNP levels are constant during stable conditions.

AB - AIMS: Here, the aim is to assess long-term clinical variation (CV) of N-terminal pro-brain natriuretic peptide (NT-proBNP) in stable chronic heart failure (CHF) patients. The proposed use of NT-proBNP for monitoring of CHF patients will require accurate information about long-term CV of the peptide. METHODS AND RESULTS: Medication, biochemical variables, and NYHA class were recorded at 1-year and 2-year follow-up in patients treated in our heart failure clinic. Only patients without changes in medication and the NYHA class who were not hospitalized or died in the period from first follow-up to 12 months after the second follow-up were included. A total of 78 patients fulfilled the criteria, and year-to-year CV was calculated to 30% (median) (range: 0-111%) (% changes range: -87 to 397%). Log transformation of NT-proBNP (skewed to the right) reduced the year-to-year CV to 4.7% (range: 0-22%) (% changes range: -18 to 38%). CONCLUSION: Long-term CV of plasma concentrations of NT-proBNP in stable CHF patients is 30%, but the variation is substantial. Therefore, high long-term CV of NT-proBNP does not necessarily carry prognostic significance within the subsequent 12 months. Plasma concentrations of NT-proBNP followed a lognormal distribution, and the low CV of log(NT-proBNP) indicate that NT-proBNP levels are constant during stable conditions.

U2 - 10.1093/eurheartj/ehl449

DO - 10.1093/eurheartj/ehl449

M3 - Journal article

VL - 28

SP - 177

EP - 182

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 2

ER -

ID: 8464815